Mihael H. Polymeropoulos - 01 Mar 2025 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role: President and CEO, Director, Chairman of the Board
Signature: /s/ Mihael H. Polymeropoulos
Issuer symbol: VNDA
Transactions as of: 01 Mar 2025
Net transactions value: -$409,905
Form type: 4
Filing time: 04 Mar 2025, 16:45:52 UTC
Previous filing: 28 Feb 2025
Next filing: 05 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VNDA	Common Stock	Tax liability	$456,955	-95,999	-4.1%	$4.76	2,265,731	01 Mar 2025	Direct	F1
transaction	VNDA	Common Stock	Purchase	$47,050	+10,000	+0.44%	$4.70	2,275,731	03 Mar 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

Content

Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.